



ANNUAL MEETING

7th- 8th November 2016

ROYAUMONT ABBAYE & FONDATION - 95270 ASNIÈRES-SUR-OISE, FRANCE

DAY 1 MONDAY 7th NOVEMBER

- 10.00** *Arrival of AtheroFlux guests in Royaumont Abbey, Asnières-sur-Oise (France)*
- 11.00-13.00** *Visit of the Abbey*
- 13.00-14.00** *Lunch*
- 14.00-14.15** **Welcome**
Philippe Sansonetti - Institut Pasteur, France
- 14.15-14.30** **General assembly & Coordinator address**
Marc Feldmann - University of Oxford, United Kingdom
- 14.30-15.00** **Fat, gut and bugs: a burning "ménage à trois"**
Philippe Sansonetti lecture - Institut Pasteur, France
- 15.00-16.00** **WP1 Discovery of key regulatory nodes within SL biosynthesis in patients with coronary artery diseases via Flux methodologies**
- The FLUX of AtheroFlux (20 mins)
Reijo Laaksonen & Terhi Vihervaara Zora (WP leader) - Zora Biosciences OY, Finland
 - iPS cells lipidomics (20 mins)
Katriina Aalto-Setälä - Tampere University Hospital, Finland
 - Discussion (20 mins)
- 16.00 16.30** *Coffee break*
- 16.30-17.30** **WP2 Genome-scale RNAi screening to reveal rate-limiting pathways in ceramide metabolism and signalling**
- New siTools on the block (20 mins)
Michael Hannus (WP leader) - siTools, Germany
 - Phosphoproteomics and lipid signaling (20 mins)
Ejsing Christer - Syddansk Universitet, Denmark
 - Discussion (20 mins)
- 17.30-18.30** **WP3 Evaluation of the significance of prospective therapeutic targets within the SL pathway in terms of inflammatory signalling**
- Immune cells sensing lipids (20 mins)
Gabrielle Paulsson-Berne (WP leader) - Karolinska Institutet, Sweden
 - The first AtheroFlux target: Cers2 (20 mins)
Tony Futerman - Weizmann Institute of Science, Israel
 - Discussion (20 mins)
- 19.00** *Networking dinner*



ANNUAL MEETING

7th- 8th November 2016

ROYAUMONT ABBAYE & FONDATION - 95270 ASNIÈRES-SUR-OISE, FRANCE

DAY 2 TUESDAY 8th NOVEMBER

09.00-10.00

AtheroFlux Mini-symposium

3 short presentations from young investigators

- Summary of training activities:

Joao Diniz De Araujo - Institut Pasteur, France

Avraam El Hamidieh - Biomedical Research Foundation Academy of Athens, Greece

- Toll-like receptor signalling

Natacha Zanin - University of Oxford, United Kingdom

10.00-10.30

Coffee break

10.30-11.30

WP4 Evaluation of biodistribution, bioactivity and pro-atherogenic properties of alterations in SL metabolism

- Inflammatory signalling (20 mins)

Evangelos Andreakos (WP leader) - Biomedical Research Foundation Academy of Athens, Greece

- Bacteria and lipids (20 mins)

Joao Diniz De Araujo - Institut Pasteur, France

- Discussion (20 mins)

11.30-12.30

WP5 Development of LNA oligonucleotide-based therapeutics targeting SL metabolism and its associated signalling

- LNA treatments for inflammation (20 mins)

Marie Wickström Lindholm (WP leader) - Roche Innovation Center Copenhagen, Denmark

- Mass cytometry (20 mins)

Claudia Monaco - University of Oxford, United Kingdom

- Discussion (20 mins)

12.30-14.00

Lunch

14.00-15.00

WP6 Management, Review and Assessment

WP7 Dissemination and Diffusion of project results

- Paola Cesaroni - ALTA Ricerca e Sviluppo in Biotecnologie (30 mins)

- How to implement training activities? - Discussion (30 mins)

15.00-17.00

AtheroFlux Steering Committee

17.00

Departures